摘要
目的探讨瑞舒伐他汀干预对急性脑卒中患者低密度脂蛋白(LDL)和高密度脂蛋白(HDL)的比值(LDL/HDL)及预后的影响。方法收集2011年3月～2012年3月来海南省农垦那大医院就诊的急性脑卒中患者120例,统计患者的临床资料、入院时的血脂,计算LDL/HDL的比值,填写神经功能缺损评分(NIHSS)、生活能力(BI)量表评分。随访6个月,统计其病死率及复发率。结果患者治疗后3、6个月LDL降低明显[(3.04±1.03)、(2.50±1.00)mmol/L],HDL升高明显[(1.54±0.10)、(2.01±0.23)mmol/L],LDL/HDL比值降低[(2.13±0.57)、(1.20±0.14)],差异均有统计学意义(均P<0.05)。患者治疗后3、6个月NIHSS评分降低明显[(20.3±4.7)、(12.0±4.5)分],BI评分升高明显[(30.4±7.9)、(42.7±10.4)分],差异均有统计学意义(均P<0.05)。治疗后3、6个月比较,差异无统计学意义。120例患者经随访6个月,无病死患者,再发11例(9.12%),患者整体生活质量改善显著。结论瑞舒伐他汀可显著降低急性脑卒中患者LDL/HDL,改善神经功能缺损,提高其生活能力,减少病死率,降低复发,效果显著,可在临床推广应用。
Objective To explore the influence of Rosuvastatin Calcium on LDL/HDL ratio and prognosis of acute cerebral apoplexy. Methods The medical records of 120 patients with acute cerebral apoplexy in Agricultural Reclamation Nada Hospital of Hainan Province from March 2011 to March 2012 were collected, and the clinical data of patients, blood lipids on admission to hospital, the calculation of the LDL/HDL ratio, nerve function defect （NIHSS） scores, life ability （BI） rating scale were counted. Statistics were followed up for 6 months, the ease fatality rate and recurrence rate were counted. Results Patients with LDL [（3.04±1.03）, （2.50±1.00） mmol/L] decreased obviously after treatment for 3, 6 months, HDL [（1.54±0.10）, （2.01±0.23） mmol/L] increased, LDL/HDL ratio [（2.13±0.57）, （1.20±0.14）] reduced, there were statistically significant differences （all P 〈 0.05）. Patients with NIHSS score after treatment for 3, 6 months decreased significantly [（20.3±4.7）, （12.0±4.5） scores], the BI score [（30.4±7.9）, （42.7±10.4） scores] increased significantly, the differences were statistically significant （all P 〈 0.05）. The differences between 3 months and 6 months after treatment were no statistically significant. 120 cases of patients were followed up for 6 months, no dead patients, the recurrence were 11 cases （9.12%）, patients with the overall quality of life improved significantly. Conclusion Rosuvastatin Calcium can significantly reduce LDL/HDL in patients with acute cerebral apoplexy, improve nerve function defect, and improve the living ability, reduce the case fatality rate, reduce the recurrence, with significant effect, which can be popularized in clinical application.
出处
《中国医药导报》
CAS
2013年第20期69-70,76,共3页
China Medical Herald
基金
海南省医学普通科研立项课题(琼卫2012-PT-95)
